Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | CPX-351 |
Trade Name | Vyxeos |
Synonyms | Liposome-encapsulated Daunorubicin-Cytarabine |
Drug Descriptions |
Vyxeos (CPX-351) is a liposomal formulation of cytarabine and daunorubicin with anti-tumor activities (PMID: 25223583). Vyxeos (CPX-351) is FDA approved for use in patients with newly-diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes (FDA.gov). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C67504 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CPX-351 | CPX-351 | 1 | 18 |
CPX-351 + Cytarabine + Filgrastim + Fludarabine | CPX-351 Cytarabine Filgrastim Fludarabine | 0 | 1 |
CPX-351 + Enasidenib | CPX-351 Enasidenib | 0 | 2 |
CPX-351 + Gemtuzumab ozogamicin | CPX-351 Gemtuzumab ozogamicin | 0 | 3 |
CPX-351 + Glasdegib | CPX-351 Glasdegib | 0 | 1 |
CPX-351 + Ivosidenib | CPX-351 Ivosidenib | 0 | 1 |
CPX-351 + Midostaurin | CPX-351 Midostaurin | 0 | 1 |
CPX-351 + Palbociclib | CPX-351 Palbociclib | 0 | 1 |
CPX-351 + Quizartinib | CPX-351 Quizartinib | 0 | 2 |
CPX-351 + Ruxolitinib | CPX-351 Ruxolitinib | 0 | 1 |
CPX-351 + Venetoclax | CPX-351 Venetoclax | 0 | 3 |